Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack

Publisher Website
Google Scholar
Abstract
Background After a first ischaemic stroke, further vascular events due to thromboembolism (especially myocardial infarction and recurrent stroke) are common and often fatal. Anticoagulants could potentially reduce the risk of such events, but any benefits could be offset by an increased risk of fatal or disabling haemorrhages. Objectives To assess the effect of prolonged anticoagulant therapy (compared with placebo or open control) following presumed non‐cardioembolic ischaemic stroke or transient ischaemic attack. Search methods We searched the Cochrane Stroke Group trials register. We contacted companies marketing anticoagulant agents. The most recent search for this review was carried out in August 2002. Selection criteria Randomised and quasi‐randomised trials comparing at least one month of anticoagulant therapy with control in people with previous presumed non‐cardioembolic ischaemic stroke or transient ischaemic attack. Data collection and analysis Two review authors independently selected trials for inclusion, assessed trial quality and extracted the data. Main results Eleven trials involving 2487 participants were included. The quality of the nine trials which predated routine computerised tomography scanning and the use of the International Normalised Ratio to monitor anticoagulation was poor. There was no evidence of an effect of anticoagulant therapy on either the odds of death or dependency (two trials, odds ratio (OR) 0.83, 95% confidence interval (CI) 0.52 to 1.34) or of 'non‐fatal stroke, myocardial infarction, or vascular death' (four trials, OR 0.96, 95% CI 0.68 to 1.37). Death from any cause (OR 0.95, 95% CI 0.73 to 1.24) and death from vascular causes (OR 0.86, 95% CI 0.66 to 1.13) were not significantly different between treatment and control. The inclusion of two recent completed trials did not alter these conclusions. There was no evidence of an effect of anticoagulant therapy on the risk of recurrent ischaemic stroke (OR 0.85, 95% CI 0.66 to 1.09). However, anticoagulants increased fatal intracranial haemorrhage (OR 2.54, 95% CI 1.19 to 5.45), and major extracranial haemorrhage (OR 3.43, 95% CI 1.94 to 6.08). This is equivalent to anticoagulant therapy causing about 11 additional fatal intracranial haemorrhages and 25 additional major extracranial haemorrhages per year for every 1000 patients given anticoagulant therapy. Authors' conclusions Compared with control, there was no evidence of benefit from long‐term anticoagulant therapy in people with presumed non‐cardioembolic ischaemic stroke or transient ischaemic attack, but there was a significant bleeding risk.